Taiwan · Delayed Price · Currency is TWD Allied Biotech Statistics
Total Valuation
Allied Biotech has a market cap or net worth of TWD 2.59 billion. The enterprise value is 2.12 billion.
| Market Cap | 2.59B |
| Enterprise Value | 2.12B |
Important Dates
The next estimated earnings date is Wednesday, November 18, 2026.
| Earnings Date | Nov 18, 2026 |
| Ex-Dividend Date | Jun 4, 2026 |
Share Statistics
Allied Biotech has 109.08 million shares outstanding. The number of shares has increased by 0.71% in one year.
| Current Share Class | 109.08M |
| Shares Outstanding | 109.08M |
| Shares Change (YoY) | +0.71% |
| Shares Change (QoQ) | +2.33% |
| Owned by Insiders (%) | 8.05% |
| Owned by Institutions (%) | 11.38% |
| Float | 66.99M |
Valuation Ratios
The trailing PE ratio is 15.35.
| PE Ratio | 15.35 |
| Forward PE | n/a |
| PS Ratio | 2.70 |
| PB Ratio | 1.65 |
| P/TBV Ratio | 1.65 |
| P/FCF Ratio | 19.94 |
| P/OCF Ratio | 11.59 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.06, with an EV/FCF ratio of 16.34.
| EV / Earnings | 13.66 |
| EV / Sales | 2.21 |
| EV / EBITDA | 10.06 |
| EV / EBIT | 13.75 |
| EV / FCF | 16.34 |
Financial Position
The company has a current ratio of 1.92, with a Debt / Equity ratio of 0.46.
| Current Ratio | 1.92 |
| Quick Ratio | 1.34 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | 3.41 |
| Debt / FCF | 5.53 |
| Interest Coverage | 11.55 |
Financial Efficiency
Return on equity (ROE) is 11.28% and return on invested capital (ROIC) is 9.57%.
| Return on Equity (ROE) | 11.28% |
| Return on Assets (ROA) | 4.04% |
| Return on Invested Capital (ROIC) | 9.57% |
| Return on Capital Employed (ROCE) | 9.81% |
| Weighted Average Cost of Capital (WACC) | 4.52% |
| Revenue Per Employee | 23.95M |
| Profits Per Employee | 3.88M |
| Employee Count | 40 |
| Asset Turnover | 0.40 |
| Inventory Turnover | 1.17 |
Taxes
In the past 12 months, Allied Biotech has paid 43.38 million in taxes.
| Income Tax | 43.38M |
| Effective Tax Rate | 21.85% |
Stock Price Statistics
The stock price has increased by +30.58% in the last 52 weeks. The beta is 0.20, so Allied Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | +30.58% |
| 50-Day Moving Average | 24.49 |
| 200-Day Moving Average | 26.42 |
| Relative Strength Index (RSI) | 40.39 |
| Average Volume (20 Days) | 55,858 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Allied Biotech had revenue of TWD 957.93 million and earned 155.13 million in profits. Earnings per share was 1.54.
| Revenue | 957.93M |
| Gross Profit | 375.06M |
| Operating Income | 154.08M |
| Pretax Income | 198.51M |
| Net Income | 155.13M |
| EBITDA | 209.17M |
| EBIT | 154.08M |
| Earnings Per Share (EPS) | 1.54 |
Balance Sheet
The company has 1.02 billion in cash and 716.97 million in debt, with a net cash position of 302.16 million or 2.77 per share.
| Cash & Cash Equivalents | 1.02B |
| Total Debt | 716.97M |
| Net Cash | 302.16M |
| Net Cash Per Share | 2.77 |
| Equity (Book Value) | 1.57B |
| Book Value Per Share | 14.42 |
| Working Capital | 826.11M |
Cash Flow
In the last 12 months, operating cash flow was 223.00 million and capital expenditures -93.36 million, giving a free cash flow of 129.65 million.
| Operating Cash Flow | 223.00M |
| Capital Expenditures | -93.36M |
| Depreciation & Amortization | 55.55M |
| Net Borrowing | -241.01M |
| Free Cash Flow | 129.65M |
| FCF Per Share | 1.19 |
Margins
Gross margin is 39.15%, with operating and profit margins of 16.08% and 16.19%.
| Gross Margin | 39.15% |
| Operating Margin | 16.08% |
| Pretax Margin | 20.72% |
| Profit Margin | 16.19% |
| EBITDA Margin | 21.84% |
| EBIT Margin | 16.08% |
| FCF Margin | 14.05% |
Dividends & Yields
This stock pays an annual dividend of 1.25, which amounts to a dividend yield of 5.27%.
| Dividend Per Share | 1.25 |
| Dividend Yield | 5.27% |
| Dividend Growth (YoY) | 25.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 77.55% |
| FCF Payout Ratio | 61.01% |
| Buyback Yield | -0.71% |
| Shareholder Yield | 4.56% |
| Earnings Yield | 6.51% |
| FCF Yield | 5.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 8 |